Manufacturing trials

Futura Medical PLC
25 April 2005


Press Release                                                      25 April 2005

                               Futura Medical Plc
                          CSD500 Manufacturing trials


Futura Medical plc ('Futura' or 'the Company'), the AIM-listed pharmaceutical
and medical device group that develops innovative products for the sexual
healthcare market, today announces completion of initial manufacturing trials of
its Condom Safety Device ('CSD500').

This manufacturing trial follows encouraging stability and compatibility results
on the gel in laboratory studies and will generate essential data to confirm the
laboratory data.  This will facilitate the submission of an application to EU
regulators for CSD500 marketing authorisation later in the year.

CSD500 is a latex condom incorporating within its teat a gel to help healthy men
maintain an erection throughout intercourse, thereby reducing the likelihood of
condom slippage.

James Barder, Chief Executive of Futura, said: 'This is an important step
towards the completion of the dossier for CSD500.'


For further information:
 Futura Medical plc
 James Barder, Chief Executive                         Tel: [phone]
 mail to: [e-mail]               www.futuramedical.co.uk

Media enquiries:
 Abchurch
 Peter Curtain / Samantha Robbins                      Tel: [phone]
 mailto: [e-mail]              www.abchurch-group.com


Notes to Editors:

Futura Medical is an AIM-listed pharmaceutical drug and medical device group
developing innovative products for sexual health.  The Company is developing a
portfolio of products with the intention of licensing their manufacture and
distribution to major pharmaceutical and healthcare groups.   Several agreements
have been signed.

Futura's primary focus is on Over the Counter ('OTC') products with particular
appeal to men and women who are reluctant to discuss potentially embarrassing
sexual matters with their doctors.  The Company has three products in
development and is in discussions to expand the pipeline.

CSD500 is a latex condom incorporating within its teat a gel to help healthy men
maintain an erection throughout intercourse, thereby reducing the likelihood of
condom slippage.  An exclusive agreement for worldwide distribution has been
signed with SSL International plc, the maker of Durex(TM).

FLD500, aimed primarily at female partners of male condom users, will help women
maintain lubrication during intercourse, thereby reducing the risk of condom
failure.  SSL International plc holds an option for worldwide distribution
rights.

In trials, MED2002, a locally applied gel for erectile dysfunction ('ED'), has
shown dramatically improved dermal absorption rates and a dose-ranging study is
currently being conducted prior to commencement of a Phase III study in late
2005.  Futura has entered into exclusive discussions with a major global
pharmaceutical group for the worldwide development and marketing of MED2002.

A trial to assess the safety of MED2002 in angina patients has already been
successfully completed.  Subject to regulatory approval the Company intends to
recruit men suffering from ED with mild to moderate angina into the Phase III
trial.  Normal medications taken by angina patients prevent the use of available
ED treatments such as Viagra(TM), Cialis(TM) and Levitra(TM).


www.futuramedical.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange